Uncategorized
Bayer, Johns Hopkins to develop ophthalmic therapies for retinal diseases
Bayer HealthCare and Johns Hopkins University have entered into a 5-year collaboration agreement to develop ophthalmic therapies for retinal diseases, according to a press release. Under the agreement, Bayer and Wilmer Eye Institute of Johns Hopkins will conduct research to evaluate new targets and disease mechanisms, drug delivery technologies and biomarkers for retinal diseases with high unmet medical need, the release said.